Combination therapy for age-related macular degeneration

Retina

Volumn 29, Issue SUPPL. 6, 2009, Pages

  Patel, Samir ^a  

^a Ophthotech Corp   (United States)

Author keywords

Age related macular degeration and anti PDGF (E10030); Anticomplement; Combination therapy and AMD; Integrin a5b1 (Volociximab)

Indexed keywords

E 10030; PLATELET DERIVED GROWTH FACTOR; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB;

ANGIOGENESIS; CLINICAL TRIAL; COMPLEMENT INHIBITION; DISEASE COURSE; EXPERIMENTAL STUDY; HUMAN; INFLAMMATION; NOTE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DRUG THERAPY, COMBINATION; HUMANS; INTEGRIN ALPHA5BETA1; MACULAR DEGENERATION; PROTEIN KINASE INHIBITORS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68049135739     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ad22d5     Document Type: Note

References (18)

1. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthtalmol 2008;145:239-248.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
3. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
4. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053. (Pubitemid 43825322)
5. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295. (Pubitemid 36554699)
6. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-340.
7. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003;314:131-144.
8. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
9. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-1362. (Pubitemid 30660012)
10. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-286. (Pubitemid 44497002)
11. Bhaskar V, Fox M, Breinberg D, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008;26:7-12.
12. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005;112:2076-2080. (Pubitemid 41720983)
13. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005;123:774-782. (Pubitemid 41056598)
14. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-390. (Pubitemid 40530070)
15. Umeda S, Suzuki MT, Okamoto H, et al. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis) FASEB J 2005;19:1683-1685. (Pubitemid 41429529)
16. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-431.
17. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 2001;15(Pt 3):390-395. (Pubitemid 32600863)
18. Giese MJ, Mondino BJ, Glasgow BJ, et al. Complement system and host defense against staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci 1994;35:1026-1032.